Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Torsten O. Nielsen(University of British Columbia), Michael Knauer(Breast Center), Florian Fitzal, S. Liu(BC Cancer Agency), Sean Ferree(Hospital Costa del Sol), Martin Filipits(University of Vienna), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Richard Greil(Paracelsus Medical University), Rupert Bartsch(Universitätszahnklinik Wien), Sigrun Ressler(Paracelsus Medical University), James J. Storhoff(Northwestern University), Margaretha Rudas(Comprehensive Cancer Center Vienna), Carl Schaper(Hospital Costa del Sol), Peter Dubsky(Hirslanden Klinik St. Anna), W. Kwasny(State Hospital), Brigitte Mlineritsch(Paracelsus Medical University), Marija Balić(University of Pittsburgh), J. Wayne Cowens(Nanostring Technologies (United States)), G. Steger(Aristotle University of Thessaloniki), R. Jakesz(Comprehensive Cancer Center Vienna), Christian F. Singer(Comprehensive Cancer Center Vienna), Herbert Stoeger(Medical University of Graz), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 403
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k